Augmentation of antitumor effect of adenovirus-mediated CD suicide gene therapy by cotransfer of interleukin 2 gene in melanoma-bearing mice

Chinese Medical Journal

Volumn 112, Issue 2, 1999, Pages 162-165

  Ju, Dian Wen ^a   Cao, Xuetao ^a   Tao, Qun ^a   Wang, Baomei ^a   Chen, Guoyou ^a   Yu, Yizhi ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorocytosine; Adenovirus; Antitumor immunity; Cytosine deaminase; Gene therapy; Interleukin 2

Indexed keywords

FLUOROURACIL; INTERLEUKIN 2; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENE TRANSFER; MALE; MELANOMA; MOUSE; NONHUMAN; SUICIDE GENE;

EID: 0344889056     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Deonarain MP, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Ther 1995;2:235-244.
2. Mullen CA. Metabolic suicide genes in gene therapy. Pharmac Ther 1994;63:199-207.
3. Tiberghien P. Use of suicide genes in gene therapy. J Leukoc Biol 1994;56:203-209.
4. Hirschowitz EA, Ohwada A, Pascal WR, et al. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995;6:1055-1063.
5. Szala S, Missol E, Sochanik A, et al. The use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors. Gene Ther 1996;3:1026-1031.
6. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995;154:5302-5312.
7. Savage P, Costelna D, Moore J, et al. A phase II study of continuous infusional 5-fluorouracil (5-FU) and subcutaneous interleukin-2 (IL-2) in metastatic renal cancer. Eur J Cancer 1997; 33:1149-1151.
8. Ellerhorst JA, Sella A, Amato RJ, et al. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 1997;80:2128-2132.
9. Anderson WF. Gene therapy for cancer. Hum Gene Ther 1994;5:1-2.
10. Blankenstein T, Qin Z. Cancer vaccines in gene therapy. Gene Ther 1996;3:95-96.
11. Abe J, Wakimoto H, Yoshida Y, et al. Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 1995; 121: 587-592.
12. Ju DW, Cao X, Acres B. Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a murine melanoma model. Cancer Gene Ther 1997;4:139-144.
13. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. The Lancet 1997;349:2-3.
14. Tiberghien P. Use of suicide genes in gene therapy. J Leukoc Biol 1997;56:203-209.
15. Cao X, Chen G, Zhang W, et al. Enhanced efficacy of combination of IL 2 gene and IL 6 gene transfected tumor cells in the treatment of established metastatic tumors. Gene Ther 1996;3:421-426.
16. Cao X, Zhang W, Yu Y, et al. Induction of antitumor immunity and treatment of preestablished tumors by inactivated IL 6 gene transfected melanoma cells combined with low dose IL 2. J Cancer Res Clin Oncol 1995;121:721-728.
17. Ramesh R, Munshi A, Abboud CN, et al. Expression of costimulatory molecules: B7 and ICAM up regulation after treatment with a suicide gene. Cancer Gene Ther 1996;3:373-384.